7210 Wareham Drive, Tampa, FL 33647
Nov. 4, 2025 Management reported the foillowing: Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTA VIA ® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and investment securities with no debt “We’re transforming Medifast from a […]
Medifast Reports Q3 Results – Slide Continues Read More »
Oct. 15, 2025 A new Consumer Reports investigation has found that most protein powders and shakes — dietary supplements that have exploded in popularity in recent years — contain more lead in a single serving than is considered safe to ingest in an entire day. Technically, there’s no amount of lead that is considered safe
Study Finds high levels of lead in protein powders, shakes Read More »
Sept. 12, 2025 According to an article by Food Navigator, the ketogenic diet, popular since the 1990s, is in decline, faced by consumer fatigue over restrictive requirements and strong competition from the GLP-1 medications. Analysts at Tastewise say that social mentions of keto dropped 18% by mid-year 2025 versus the prior year. Keto’s complex and
Keto Diet Is On The Decline Read More »
Sept. 3, 2025 WW announced the appointment of Alejandro Bethlen as Executive Vice President, International, effective immediately. In this role, Bethlen will oversee WeightWatchers’ business outside of the United States, driving international growth and innovation across the Company’s global footprint. “Alejandro’s international experience and commercial leadership make him uniquely suited to advance our growth outside
Weight Watchers Hires New International V.P. Read More »
August 6, 2025 Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of U.S. tariffs, coupled with continued competition from compounded drugs sold illegally. Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and
Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally Read More »
August 5, 2025 Noom is not giving up in the fight to provide GLP-1 drugs, despite pressure from Novo and Eli Lilly to stop selling compounded meds. It is now offering a “micro dose” plan. This program provides access to GLP-1 medication (if prescribed by a clinician), but at a lower, “microdose” level compared to
Noom To Offer GLP-1 Microdose Plan Read More »
July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the
Weight Watchers Expands Collaboration With Novo Nordisk Read More »
June 24, 2025 Hims & Hers stock plummeted nearly 35% Monday after Novo Nordisk announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims’ telehealth platform. Novo Nordisk said that Hims & Hers was breaking the law by continuing to sell copycat semaglutide, the key ingredient in Wegovy, alongside
Novo Nordisk Ends Wegovy Sales Deal With Hims & Hers Read More »
May 1, 2025 The National Consumers League (NCL) – a leading non-profit fighting fraud in the marketplace – today released a white paper as a blueprint for policy changes to combat the flood of false information circulating online about GLP-1 products and launched an ambitious national anti-disinformation effort called the Weight Truth with the online
April 12, 2025 We noticed a post on Instagram today that pitches a company that will set up a medical weight loss program, using GLP-1 drugs for gyms. We shouldn’t be surprised. Everyone else has entered the GLP-1 gold rush, including med spas, so why not gyms as well? The company offering this “opportunity” is
Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded Read More »